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studies.  
Possible future options may include the addition WBRT with 
doses per fraction of <3 Gy and sparing of the hippocampus 
to reduce the risk of neurocognitive decline. Patients with a 
limited number of brain metastases who are not candidates 
for SRS, FSRT and neurosurgery or do not wish such a 
treatment may receive WBRT plus a simultaneous integrated 
boost (SIB) to the metastatic lesions.     
   
SP-0003   
Update on current consensus agreement on lung palliative 
radiotherapy 
A. Bezjak1 
1Princess Margaret Cancer Centre, Dept of Radiation 
Oncology, Toronto, Canada  
  
Background: Despite many advances in management of non-
small cell lung cancer (NSCLC), there is still a significant role 
for palliative radiotherapy (RT) - both external beam , and 
less often, brachytherapy, for symptomatic management of 
patients with symptoms due to their thoracic disease, 
including cough, hemoptysis, dyspnea and chest pain. Many 
fractionation schedules have been found to be effective, and 
practices differ across centers and countries (1).  The Third 
International Consensus Conference Workshop was held at 
ASTRO meeting in 2010 (2),followed by the publication of the 
ASTRO evidence-based clinical practice guideline for 
palliative thoracic RT in lung cancer (3) that favoured shorter 
RT schedules as providing good symptomatic relief with fewer 
side-effects, and highlighted the lack of evidence on how to 
integrate concurrent chemotherapy with palliative RT.  
Methods: Given the importance of remaining current with 
evidence in the management of patients with metastatic 
disease, the Fourth International Consensus Conference 
Workshop on Palliative Radiotherapy was convened to 
coincide with the 2015 ESTRO Meeting.  Attendees are 
planning to discuss research updates that have been 
published since the 2010 International Conference, and 
discuss areas of controversy and questions that require 
further evidence. 
Results: The Cochrane review of palliative RT for patients 
with thoracic symptoms from NSCLC has been recently 
updated and published (4). It includes 14 randomized 
controlled trials (RCTs) and more than 3500 patients. All 
trials confirmed symptom palliation from the variety of RT 
regimens, and relatively mild toxicity with shorter RT 
schedules. The evidence that higher dose palliative RT 
prolongs survival is not strong, limited in part by the 
heterogeneity among studies. A more recent RCT (5, 6) not 
included in the Cochrane review  compared chemotherapy to 
chemotherapy with concurrent moderate dose RT (42Gy/15 
fr) and demonstrated improved survival but at the expense of 
toxicity, although quality of life was maintained.  Other 
studies and evidence will be discussed at the workshop.  
Conclusion: The results of the 2015 ESTRO International 
Consensus Conference Workshop will identify current 
evidence and best practices as well as current research and 
clinical questions, and will set the stage for the Fifth 
Conference to be held in 2020. 
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Radiation therapy for metastases of the liver includes number 
of techniques ranging from whole liver radiation therapy 
(WLRT), selective internal radiation therapy (SIRT), 
brachytherapy, conformal fractionated radiotherapy to 
stereotactic techniques (SBRT). WLRT is considered palliative 
and non-ablative whereas SBRT with high doses is ablative 
and a potentially curative therapy. 
Five years back we had only few publications on the outcome 
after radiotherapy for liver metastases. Due to the relatively 
low quality of the primary literature, it was decided not to 
write a guideline for SBRT of metastases. Instead, the ASTRO, 
CARO, ESTRO and TROG working group wrote a review of 
published evidence on radiotherapy technologies and clinical 
outcome in therapy of liver metastases1.  
The review was followed by an international survey to 
describe the utilization of radiation therapy for liver 
metastases2. The survey revealed an increasing utilization of 
radiation therapy in general and SBRT in particular for 
therapy of liver metastases.  
A number of retrospective and prospective studies have been 
published since and there are initiatives to unite forces and 
contribute to large multi-institutional databases. We are still 
awaiting a successful prospective trial within this field.  
The liver session will focus on perspectives within the field 
for the next five years.  
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